Abstract
Aim:
This analysis investigates incidence and time course of rash in the EURTAC study.
Materials & methods:
Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy.
Results:
Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment.
Conclusion:
Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.
Keywords:
EGFR; erlotinib; non-small-cell lung cancer; rash; safety.
Publication types
-
Clinical Trial, Phase III
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / complications*
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / genetics*
-
Carcinoma, Non-Small-Cell Lung / mortality
-
ErbB Receptors / genetics*
-
Erlotinib Hydrochloride
-
Exanthema / drug therapy
-
Exanthema / epidemiology
-
Exanthema / etiology*
-
Exanthema / prevention & control
-
Humans
-
Incidence
-
Kaplan-Meier Estimate
-
Lung Neoplasms / complications*
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / mortality
-
Mutation*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Quinazolines / administration & dosage
-
Quinazolines / adverse effects*
-
Time Factors
-
Treatment Outcome
Substances
-
Protein Kinase Inhibitors
-
Quinazolines
-
Erlotinib Hydrochloride
-
ErbB Receptors